Boundless Bio to Present at the Guggenheim Oncology Conference

Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA in oncogene amplified cancers, announced that its Chief Executive Officer, Zachary Hornby, will present at the Guggenheim Oncology Conference, which will take place virtually.

Feb. 2, 2022 13:00 UTC

SAN DIEGO--(BUSINESS WIRE)-- Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Executive Officer, Zachary Hornby, will present at the Guggenheim Oncology Conference, which will take place virtually. Presentation details are as follows:

Date: Friday, February 11, 2022
Time: 2:00 PM – 2:25 PM EST

About Boundless Bio

Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

For more information, visit www.boundlessbio.com.

Follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220202005153/en/

Contacts

James Lee
Director of Business Development
Boundless Bio
jlee@boundlessbio.com

Source: Boundless Bio

MORE ON THIS TOPIC